Method for treatment of blood tumor using anti-TIM-3 antibody
Disclosed is a therapeutic method including administering a TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(−)CD34(+)CD38(−) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody or its TIM-3 binding fragment to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)).
1. A method for detecting blood tumor in which a cell expressing T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) is recognized in a cell in bone marrow or peripheral blood from a biological sample derived from a subject, using an anti-TIM-3 antibody or its TIM-3 binding fragment, wherein the cell is at least one cell fraction of (a) Lin(−)CD34(+)CD38 (+) or (b) Lin(−)CD34(−).
2. The method according to claim 1 , wherein the blood tumor is acute myelogenous leukemia.
3. The method according to claim 1 , wherein the blood tumor is lymphoma, myelodysplastic syndromes or chronic myeloid leukemia.
4. The method according to claim 1 , wherein the blood tumor is recurrence and/or refractory.
5. The method according to claim 1 , wherein the anti-TIM-3 antibody is an anti-TIM-3 monoclonal antibody.
6. The method according to claim 5 , wherein the anti-TIM-3 monoclonal antibody is an antibody having antibody-dependent cell-mediated cytotoxicity activity and/or complement dependent cytotoxicity activity.